Annual report pursuant to Section 13 and 15(d)

Significant Accounting Policies (Details Narrative)

v3.23.1
Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Product Information [Line Items]      
Foreign Currency Transaction Gain (Loss), before Tax $ 42,000 $ 74,000  
Cash and Cash equivalents 10,041,000 20,608,000  
Contract assets from continuing operations 0 70,000  
Contract liabilities from continuing operations 72,000 74,000  
Contract with customer discontinued   75,000  
Contract with customer liability current discontinued operation 43,000 1,900,000  
Accounts receivable, allowance for credit loss, current 0 0  
Prepaid expense $ 797,000 1,000,000.0  
Estimated useful life The estimated useful life of equipment is five years    
Goodwill 2,164,000
Goodwill impairment 2,164,000 20,216,000  
Net deferred tax asset  
Estimated useful lives of assets 10 years    
Intangible assets remaining $ 0 8,787,000  
Amortization of Intangible Assets 0 713,000  
Research and development expense 6,772,000 4,273,000  
Advertising costs 28,000 34,000  
Vivo Pharm [Member]      
Product Information [Line Items]      
Goodwill 22,400,000    
Vivo Pharm Pty Ltd [Member]      
Product Information [Line Items]      
Goodwill impairment 2,200,000 $ 20,200,000  
Directors and Officers [Member]      
Product Information [Line Items]      
Premiums receivable $ 2,700,000    
Three Customers [Member] | Trade Accounts Receivable [Member] | Customer Concentration Risk [Member]      
Product Information [Line Items]      
Concentration Risk, Percentage 100.00%    
Accounts receivable net $ 71,000    
Four Customers [Member] | Trade Accounts Receivable [Member] | Customer Concentration Risk [Member]      
Product Information [Line Items]      
Concentration Risk, Percentage   78.00%  
Accounts receivable net   $ 262,000  
Research and Development Expense [Member]      
Product Information [Line Items]      
Other Receivables 252,000 100,000  
Reduction in payroll tax expenses 252,000 205,000  
Money Market Funds [Member]      
Product Information [Line Items]      
Cash and Cash equivalents $ 8,600,000 $ 12,000,000.0